RespireRx Pharmaceuticals Inc.
RSPI · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $1 | $1 | $1 |
| G&A Expenses | $1 | $2 | $3 | $1 |
| SG&A Expenses | $1 | $2 | $3 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $3 | $3 | $2 |
| Operating Income | -$2 | -$3 | -$3 | -$2 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$1 | -$1 | -$1 | -$0 |
| Pre-Tax Income | -$2 | -$3 | -$4 | -$2 |
| Tax Expense | -$0 | $1 | $1 | $0 |
| Net Income | -$2 | -$4 | -$5 | -$3 |
| % Margin | – | – | – | – |
| EPS | -0.036 | -0.04 | -0.22 | -6.45 |
| % Growth | 10.5% | 81.9% | 96.6% | – |
| EPS Diluted | -0.036 | -0.04 | -0.22 | -6.45 |
| Weighted Avg Shares Out | 111 | 88 | 26 | 0 |
| Weighted Avg Shares Out Dil | 111 | 88 | 26 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $0 |
| Depreciation & Amortization | -$0 | $3 | $0 | $2 |
| EBITDA | -$2 | $0 | -$4 | $0 |
| % Margin | – | – | – | – |